Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.14
ANGO's Cash to Debt is ranked lower than
52% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. ANGO: 0.14 )
ANGO' s 10-Year Cash to Debt Range
Min: 0.07   Max: 9999
Current: 0.14

0.07
9999
Equity to Asset 0.69
ANGO's Equity to Asset is ranked higher than
80% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. ANGO: 0.69 )
ANGO' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.94
Current: 0.69

0.06
0.94
Interest Coverage 3.54
ANGO's Interest Coverage is ranked lower than
53% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.94 vs. ANGO: 3.54 )
ANGO' s 10-Year Interest Coverage Range
Min: 1.19   Max: 74.68
Current: 3.54

1.19
74.68
F-Score: 4
Z-Score: 2.15
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 0.35
ANGO's Operating margin (%) is ranked higher than
65% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.17 vs. ANGO: 0.35 )
ANGO' s 10-Year Operating margin (%) Range
Min: -10   Max: 13.14
Current: 0.35

-10
13.14
Net-margin (%) -1.02
ANGO's Net-margin (%) is ranked higher than
65% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. ANGO: -1.02 )
ANGO' s 10-Year Net-margin (%) Range
Min: -8.13   Max: 8.75
Current: -1.02

-8.13
8.75
ROE (%) -0.68
ANGO's ROE (%) is ranked higher than
64% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. ANGO: -0.68 )
ANGO' s 10-Year ROE (%) Range
Min: -3.97   Max: 198.83
Current: -0.68

-3.97
198.83
ROA (%) -0.46
ANGO's ROA (%) is ranked higher than
65% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.84 vs. ANGO: -0.46 )
ANGO' s 10-Year ROA (%) Range
Min: -3.51   Max: 9.77
Current: -0.46

-3.51
9.77
ROC (Joel Greenblatt) (%) 0.86
ANGO's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.69 vs. ANGO: 0.86 )
ANGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26.38   Max: 43.53
Current: 0.86

-26.38
43.53
Revenue Growth (3Y)(%) 5.20
ANGO's Revenue Growth (3Y)(%) is ranked higher than
75% of the 265 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ANGO: 5.20 )
ANGO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 3.2   Max: 25.2
Current: 5.2

3.2
25.2
EBITDA Growth (3Y)(%) 3.70
ANGO's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ANGO: 3.70 )
ANGO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -33.8   Max: 31.3
Current: 3.7

-33.8
31.3
EPS Growth (3Y)(%) -37.00
ANGO's EPS Growth (3Y)(%) is ranked higher than
53% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.20 vs. ANGO: -37.00 )
ANGO' s 10-Year EPS Growth (3Y)(%) Range
Min: -37   Max: 100
Current: -37

-37
100
» ANGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ANGO Guru Trades in Q2 2014

Jim Simons 92,000 sh (+36.20%)
Chuck Royce 839,013 sh (+8.60%)
Steven Cohen 41,300 sh (unchged)
Mario Gabelli 86,000 sh (-9.47%)
» More
Q3 2014

ANGO Guru Trades in Q3 2014

Paul Tudor Jones 13,824 sh (New)
Jim Simons 153,160 sh (+66.48%)
Chuck Royce 848,531 sh (+1.13%)
Mario Gabelli 86,000 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2014

ANGO Guru Trades in Q4 2014

Jim Simons 371,546 sh (+142.59%)
Paul Tudor Jones 17,029 sh (+23.18%)
Mario Gabelli 83,000 sh (-3.49%)
Chuck Royce 688,331 sh (-18.88%)
» More
Q1 2015

ANGO Guru Trades in Q1 2015

Mario Gabelli 83,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 21.93
ANGO's Forward P/E is ranked higher than
79% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 60.61 vs. ANGO: 21.93 )
N/A
P/B 1.10
ANGO's P/B is ranked higher than
93% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. ANGO: 1.10 )
ANGO' s 10-Year P/B Range
Min: 0.64   Max: 6.67
Current: 1.1

0.64
6.67
P/S 1.70
ANGO's P/S is ranked higher than
82% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.21 vs. ANGO: 1.70 )
ANGO' s 10-Year P/S Range
Min: 1.03   Max: 5.62
Current: 1.7

1.03
5.62
PFCF 62.30
ANGO's PFCF is ranked lower than
66% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 91.20 vs. ANGO: 62.30 )
ANGO' s 10-Year PFCF Range
Min: 8.87   Max: 285.43
Current: 62.3

8.87
285.43
POCF 23.81
ANGO's POCF is ranked higher than
71% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.48 vs. ANGO: 23.81 )
ANGO' s 10-Year POCF Range
Min: 8.43   Max: 241.18
Current: 23.81

8.43
241.18
EV-to-EBIT 589.64
ANGO's EV-to-EBIT is ranked higher than
75% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.88 vs. ANGO: 589.64 )
ANGO' s 10-Year EV-to-EBIT Range
Min: -570.9   Max: 646.4
Current: 589.64

-570.9
646.4
Shiller P/E 126.50
ANGO's Shiller P/E is ranked higher than
76% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ANGO: 126.50 )
ANGO' s 10-Year Shiller P/E Range
Min: 33.31   Max: 146.38
Current: 126.5

33.31
146.38
Current Ratio 2.64
ANGO's Current Ratio is ranked higher than
77% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. ANGO: 2.64 )
ANGO' s 10-Year Current Ratio Range
Min: 1.95   Max: 14.28
Current: 2.64

1.95
14.28
Quick Ratio 1.48
ANGO's Quick Ratio is ranked higher than
69% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. ANGO: 1.48 )
ANGO' s 10-Year Quick Ratio Range
Min: 1.16   Max: 12.12
Current: 1.48

1.16
12.12
Days Inventory 135.02
ANGO's Days Inventory is ranked higher than
72% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 137.40 vs. ANGO: 135.02 )
ANGO' s 10-Year Days Inventory Range
Min: 94.14   Max: 174.24
Current: 135.02

94.14
174.24
Days Sales Outstanding 58.55
ANGO's Days Sales Outstanding is ranked higher than
81% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 70.03 vs. ANGO: 58.55 )
ANGO' s 10-Year Days Sales Outstanding Range
Min: 45.92   Max: 207.55
Current: 58.55

45.92
207.55

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
ANGO's Price/DCF (Projected) is ranked higher than
95% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.24 vs. ANGO: 1.00 )
ANGO' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 1.09
Current: 1

0.54
1.09
Price/Median PS Value 0.90
ANGO's Price/Median PS Value is ranked higher than
90% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. ANGO: 0.90 )
ANGO' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 2.82
Current: 0.9

0.61
2.82
Earnings Yield (Greenblatt) 0.20
ANGO's Earnings Yield (Greenblatt) is ranked higher than
66% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. ANGO: 0.20 )
ANGO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10.9
Current: 0.2

0.2
10.9
Forward Rate of Return (Yacktman) 0.03
ANGO's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. ANGO: 0.03 )
ANGO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.8   Max: 6.6
Current: 0.03

-16.8
6.6

Analyst Estimate

May15 May16
Revenue(Mil) 363 381
EPS($) 0.64 0.76
EPS without NRI($) 0.64 0.76

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company is organized in two segments: Vascular and Oncology/Surgery. The Oncology/Surgery Division includes Radiofrequency Ablation (RFA) and NanoKnife product lines. This division also includes the microwave ablation technology products obtained through the acquisition of Microsulis Medical Ltd. The Vascular division manages Fluid Management, Venous, AngioVac, Angiographic, PTA, Drainage, Thrombolytic, Micro Access Kits, Dialysis, PICC and Port product lines. The Company's product include the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. The devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures throughout the procedure. The venous products consist of our VenaCure EVLT laser system and Sotradecol. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass procedure for up to six hours. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The Acculis Microwave Tissue Ablation (MTA) System complements the full range of ablative technologies. The Company competes with Boston Scientific Corporation; Cook Medical; Cordis Corporation, a subsidiary of Johnson & Johnson, Inc.; C.R. Bard; Medical Components, Inc., or Medcomp; Arrow International, a subsidiary of TeleFlex Medical; Smiths Medical, a subsidiary of Smiths Group PLC; Vascular Solutions; Covidien subsidiaries (Kendall, VNUS, EV3) and Merit Medical
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
ANGO INVESTOR ALERT: AngioDynamics, Inc. Shareholders Encouraged to Contact The Wagner Firm... Apr 30 2015
AngioDynamics, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into... Apr 28 2015
10-Q for AngioDynamics, Inc. Apr 23 2015
ANGIODYNAMICS INC Financials Apr 15 2015
ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 14 2015
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Investigates Claims on Behalf of Investors of... Apr 13 2015
Company News for April 13, 2015 - Corporate Summary Apr 13 2015
Stocks gain for a second week in a row; GE soars on deal Apr 10 2015
Stocks gain for a second week in a row; GE soars on deal Apr 10 2015
SHAREHOLDER ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of... Apr 10 2015
US indexes higher in midday trading; GE soars on deal news Apr 10 2015
US indexes higher in midday trading; GE soars on deal news Apr 10 2015
AngioDynamics Lags Earnings on Lower Sales, View Tepid - Analyst Blog Apr 10 2015
ANGIODYNAMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 10 2015
AngioDynamics skids after 3Q report and reduced outlook Apr 09 2015
AngioDynamics skids after 3Q report and reduced outlook Apr 09 2015
Gap shares decline as sales fall at namesake store Apr 09 2015
ANGIODYNAMICS INC Files SEC form 10-Q, Quarterly Report Apr 09 2015
AngioDynamics (ANGO) Stock Declines in After-Hours Trading on Missed Earnings Apr 09 2015
AngioDynamics Re-Entering Embolization Market Apr 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK